TOMI Environmental Solutions (TOMZ) Company Report

TOMI Environmental Solutions announced the sale of a Custom Engineered System (CES) in the United Kingdom to an international pharmaceutical manufacturing organization.
The system integrates SteraMist iHP technology into Total Clean Air Limited's (TCA) modular cleanroom platform, marking the first deployment of iHP technology within TCA’s modular platform.
This collaboration establishes a repeatable, scalable, and regulator-ready model for future pharmaceutical cleanroom developments across the UK and wider international markets, representing an important step in TOMI's international growth strategy.

Jan 20, 2026, 2:15 PM

Press Release

TOMI Environmental Solutions' SteraMist iHP Technology Adopted by Cell and Gene Therapy Manufacturer

TOMZ

New Projects/Investments

TOMI Environmental Solutions, Inc. announced on December 22, 2025, that a leading Cell and Gene Therapy (CGT) manufacturer has adopted its SteraMist ionized Hydrogen Peroxide (iHP) technology for a commercial-scale facility.
This multi-staged implementation aims to strengthen the facility\u2019s Contamination Control Strategy (CCS) to meet current Good Manufacturing Practices (cGMP) requirements for developing novel genetic disease therapies.
The partnership involves the client investing in multiple SteraMist systems and TOMI providing a comprehensive standard operating procedure (SOP) development package and Installation and Operational Qualification (IQ/OQ) package.
TOMI's iHP Corporate Service team will also perform a whole-facility fogging service to ensure the environment is sterile for critical pharmaceutical processes.

Dec 22, 2025, 9:05 PM

Press Release

TOMI Environmental Solutions Secures $500,000 Purchase Order for SteraMist Integration

TOMZ

New Projects/Investments

Product Launch

TOMI Environmental Solutions (TOMZ) has received a significant signed purchase contract, including a purchase order valued at approximately $500,000, from one of the world's largest biopharmaceutical companies.
The order is for the complete integration of TOMI's SteraMist Integrated Systems (SIS) platform into critical manufacturing infrastructure, specifically for passthrough fill boxes in sterile manufacturing and advanced therapeutic production.
The SIS platform, formally launched in late 2024, is actively driving a $13 million pipeline for automated installation projects, with robust interest and anticipated orders throughout 2026 and beyond.

Dec 18, 2025, 2:00 PM

Press Release

TOMI Environmental Solutions discusses SteraMist technology and growth strategy at Sidoti conference

TOMZ

Product Launch

New Projects/Investments

Revenue Acceleration/Inflection

TOMI Environmental Solutions (TOMZ) presented its SteraMist disinfection and decontamination technology, which utilizes a low-percentage hydrogen peroxide converted into a hydroxyl radical for rapid, residue-free, and eco-friendly pathogen elimination. This technology was developed by DARPA and is registered in 50 states and over 30 countries.
The company operates on a "razor-razor blade" business model, where equipment sales drive recurring, high-margin consumable revenue, with gross margins typically around 60%-62%.
SteraMist serves diverse market segments including biotechnology/life sciences, food safety, healthcare, and commercial services, with a client list that includes Pfizer, Merck, Nestlé, and Philips.
TOMI reported a 40% growth in consumable sales for the first six months of 2025 compared to the same period in 2024. The company has a $21 million integration and built-in pipeline, with $5 million near-term for 2025 and $5 million in year-to-date bookings.

Dec 11, 2025, 7:30 PM

Transcript

TOMI Environmental Solutions Highlights SteraMist Technology and Growth Drivers

TOMZ

New Projects/Investments

Revenue Acceleration/Inflection

Product Launch

TOMI Environmental Solutions (TOMZ) presented its SteraMist disinfection technology, emphasizing its advantages such as being faster, safer, eco-friendly, leaving no residue, and demonstrating broad efficacy compared to traditional methods.
The company operates on a razor-razor blade business model, where equipment sales drive recurring, high-margin revenue from consumable solutions, with gross margins reported to be around 60%-62%.
TOMZ reported a 40% increase in consumable sales for the first half of 2025 compared to the same period in 2024, and overall revenue has increased 38% over pre-COVID levels.
Growth drivers include new OEM partnerships established in late 2024, which are building a $21 million integration and built-in pipeline, alongside a near-term pipeline of approximately $5 million for 2025.
The company is targeting significant market opportunities, including the medical device disinfection market, which is projected to grow from $24 billion in 2024 to $56 billion by 2033.

Dec 11, 2025, 7:30 PM

Transcript

TOMI Environmental Solutions discusses SteraMist technology and growth strategy at Sidoti conference

TOMZ

Product Launch

Revenue Acceleration/Inflection

New Projects/Investments

TOMI Environmental Solutions (TOMZ) presented its SteraMist disinfection technology, which uses a low-percentage hydrogen peroxide converted into a hydroxyl radical for fast, eco-friendly, and residue-free decontamination, serving key markets like biotechnology, food safety, and healthcare.
The company operates on a razor-razor blade business model, generating high-margin recurring revenue from its consumable BIT solution after equipment sales. TOMI reported 40% growth in recurring revenue for the first half of 2025 compared to the same period in 2024, with gross margins around 60%-62%.
TOMI is expanding through OEM partnerships and targeting significant market opportunities, including medical device disinfection, which is projected to grow from $24 billion in 2024 to $56 billion by 2033. The company has a $21 million integration and built-in pipeline, with $5 million in near-term opportunities for 2025 and $5 million in year-to-date bookings.

Dec 11, 2025, 7:30 PM

Transcript

TOMI Environmental Solutions Reports Q3 2025 Financial Results and Strategic Developments

TOMZ

Earnings

Revenue Acceleration/Inflection

New Projects/Investments

TOMI Environmental Solutions reported Q3 2025 revenue of $2 million, marking a 95% sequential increase over Q2 2025, though representing a 24% decline compared to Q3 2024. The company posted a net loss of approximately $450,000, or $0.02 per share, while maintaining a 61% gross profit margin.
Recurring BIP solution sales increased 21% year-to-date in 2025, driven by a focus on existing customer engagement.
The sales order backlog reached $1.3 million by October 31, 2025, up from $0.9 million at quarter-end, and the active pipeline surpassed $15 million, with approximately $3 million in pending SteraMist integration contracts expected to close by year-end.
A key development is the FDA's broadened approval of hydrogen peroxide for use in food for human consumption, which is anticipated to open new markets in food safety for SteraMist technology.
To support future growth and strategic initiatives, TOMI entered an equity purchase agreement with Hudson Global Ventures, providing the flexible right to sell up to $20 million in common stock over a 24-month period.

Nov 14, 2025, 9:30 PM

Transcript

TOMI Environmental Solutions Reports Q3 2025 Results with Sequential Revenue Growth and New FDA Approval

TOMZ

Earnings

Revenue Acceleration/Inflection

New Projects/Investments

TOMI Environmental Solutions reported Q3 2025 revenue of $2 million, representing a 95% sequential increase over Q2, driven by strong equipment sales and a 21% year-to-date increase in recurring BIP solution sales.
Despite the sequential growth, Q3 2025 revenue declined 24% year-over-year from $2.5 million in Q3 2024, resulting in a net loss of $450,000 or $0.02 per share, compared to a net income of $58,000 in the prior year period. The company maintained a strong gross profit margin of 61% for both Q3 2025 and Q3 2024.
The sales order backlog reached $0.9 million at quarter-end, growing further to $1.3 million by October 31, with an active pipeline surpassing $15 million.
A significant regulatory development was the FDA's broadened approval of hydrogen peroxide as a safe disinfectant in food for human consumption, which is expected to open new market opportunities in the multi-billion-dollar food safety sector.
On November 5th, TOMI entered into an equity purchase agreement with Hudson Global Ventures, providing the flexibility to sell up to $20 million in common stock over a 24-month period to fund strategic goals and growth initiatives.

Nov 14, 2025, 9:30 PM

Transcript

TOMI Environmental Solutions Reports Q3 2025 Results with Revenue Increase and New Market Opportunities

TOMZ

Earnings

Revenue Acceleration/Inflection

New Projects/Investments

TOMI Environmental Solutions reported Q3 2025 revenue of $2 million, representing a 95% sequential increase over Q2 2025, though a 24% decline compared to Q3 2024.
The company posted a net loss of $450,000, or $0.02 per share, for Q3 2025, while maintaining a strong gross profit margin of 61%.
Sales order backlog was $0.9 million at quarter-end, growing to $1.3 million by October 31, with an active pipeline surpassing $15 million.
A significant development was the FDA's broadened approval of hydrogen peroxide as a safe disinfectant for food, which is expected to open new markets in the food safety industry for SteraMist technology.
TOMI entered into an equity purchase agreement with Hudson Global Ventures, providing the flexibility to sell up to $20 million in common stock over a 24-month period to fund strategic initiatives.

Nov 14, 2025, 9:30 PM

Transcript

TOMI Environmental Solutions, Inc. Reports Q3 2025 Financial Results and Outlines Growth Initiatives

TOMZ

Earnings

Revenue Acceleration/Inflection

New Projects/Investments

TOMI Environmental Solutions, Inc. reported Q3 2025 revenues of $2.0 million, marking a 95% sequential increase over Q2 2025, with a gross profit margin of 61%. However, the company recorded a net loss of $(450,000), or $(0.02) per basic and diluted share, for the quarter.
The company demonstrated continued international expansion, with nearly 36% of Q3 revenue generated internationally. The sales order backlog grew to $0.9 million at quarter-end and further expanded to $1.3 million as of October 31, 2025, with approximately $3 million in pending contracts expected to close before year-end.
To support its growth initiatives, TOMI secured an equity line of credit for up to $20,000,000 and plans for a universal shelf registration up to $50,000,000. Additionally, the FDA broadened the permitted use of Hydrogen Peroxide on September 18, 2025, significantly expanding the potential application of SteraMist iHP technology.